Popular Articles
Cellulite Treatment

HearAtLast To Launch Exclusive Groundbreaking Neuro-CompensatorTM Technology Hearing Aids From VitaSound
HearAtLast Holdings, Inc. (PINKSHEETS: HRAL), a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced that in keeping with its tradition of bringing innovative new products to consumers, the Company announces the unveiling of breakthrough hearing products based on the Neuro-Compensator™ algorithm technology from VitaSound Audio.
generic viagra online
Pharmaceutical Company Manager Sentenced For Off-Label Marketing
A Branchburg, NJ, woman was sentenced for violating the Food, Drug and Cosmetic Act, for marketing the drug Bextra for uses and dosages that were not approved by the Food and Drug Administration.
News of the day
Researchers Develop Key Brake For Immune Cells In Petri Dish -- Hope For Easier Organ Transplantation?
Scientists from the Helmholtz Center for Infection Research in Braunschweig, Germany and the Medical School Hannover, Germany have succeeded in treating immune cells in a way that enables them to inhibit unwanted immune reactions such as organ rejection. Their results have now been published in the current issue of the scientific journal Journal of Cellular and Molecular Medicine.
Endocrinology

UQ Scientist's Outstanding Pain Management Research Recognised

A UQ Science researcher has received a prestigious honorary fellowship for her long-time work into understanding the underlying mechanisms of pain. Professor Maree Smith has been awarded the Honorary Fellowship by the Australian and New Zealand College of Anaesthetists" Faculty of Pain Medicine. The Faculty of Pain Medicine admits distinguished persons who have made a notable contribution to the advancement of the science and practice of pain medicine, but are not practising pain medicine in Australia or New Zealand. Executive Director of UQ"s Centre for Integrated Preclinical Drug Development and its commercial arm, TetraQ, Professor Smith said she was very surprised to be honoured. "When I got the letter and opened it, I just thought "wow", I didn"t even know they did this," she said. "I feel really flattered and honoured, my research team and I have been working away in the field for about two decades now because that"s what you need to do in order to make a difference, I never expected to get recognised for it." Pain medicine is a multidisciplinary field of specialist medical practice that has matured relatively recently. The field recognises the management of severe pain problems requires the skills of more than one medical discipline. Professor Smith has specialist expertise in pre-clinical drug development as well as the mechanistic basis of pain and its pharmacological management. As TetraQ CEO, a leading Australian preclinical drug development contract research organisation based at UQ, Professor Smith is in a unique position to further pain medicine. "At TetraQ we sit in the translational research space," she said. "We assist universities and small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the pharmacy. "We perform the preclinical drug trials, showing these drugs are efficacious - they do what the company says they do - and that they are safe to go on to human trials." This isn"t the first award Professor Smith has received for her contributions to science, in 2008 she received the Women in Technology Biotech Outstanding Achievement Award. And in 2003, Professor Smith was awarded a "Trailblazer Challenge" award by UniQuest, for developing new treatments for the pain caused by sciatica and other forms of nerve damage. The FPM is the body responsible for training, education and standards for Pain Medicine in Australia and New Zealand. The University of Queensland


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):